The clinical and instrumental rationale for the choice of therapy of arterial hypertension in the patients presenting with diabetes mellitus
https://doi.org/10.14341/probl20125868-12
Abstract
Cardiovascular disorders are the main cause of high disability and mortality rates among the patients with diabetes mellitus. The objective of the present work was to estimate the clinical and hemodynamic characteristics during the treatment of arterial hypertension with the use of olmesartan (hypertension/angiotensin II receptor antagonist, ARA) in the patients with type 2 diabetes mellitus suffering diastolic heart failure. The study included 56 patients (26 men and 30 women) of the mean age 58.2±5.3 years. They were given a course of olmesartan (cardosal) therapy 40 weeks in duration. This treatment was shown to result in positive dynamics of structural and geometric characteristics of the left ventricle and its diastolic function in conjunction with the improvement of the vasomotor function of arterial endothelium.
About the Authors
I. P. Tatarchenko
Pensas Institute of Post Studies
Russian Federation
Russian Federation
N. V. Pozdnyakova
Pensas Institute of Post Studies;
Medical Care Unit № 59, Rensa
Russian Federation
Russian Federation
A. G. Mordovina
Pensas Institute of Post Studies;
Medical Care Unit № 59, Rensa
Russian Federation
Russian Federation
References
1. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М: МИА 2006.
2. Basta G., Del Turco S., De Caterina R. Advanced glycation endproducts: implications for accelerated atherosclerosis in diabetes. Recenti Prog Med 2004; 95: 67—80.
3. Grewal J., McCully R.B., Kane G.C., Ommen S.R. Left ventricular function and exercise capacity. JAMA 2009; 301: 286—294.
4. Ganau A., Devereux R.B., Roman M.J. Koren M.I, Mensah G.A. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550—1558.
5. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I. Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive deteсtion of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111—1115.
6. Velliquette R.A., Ernsberger P. Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 2003; 307: 1104—1111.
7. Дедов И.И., Александров А.А. Сахарный диабет и антагонисты АТ1-рецепторов: в поисках золотого ключика. Рус мед журн 2005; 11: 11—16.
8. Ohara T., Little W.C. Evolving focus on diastolic dysfunction in patients with coronary artery disease. Curr Opin Cardiol 2010; 25(6):613—621.
9. Paulus W.J. Novel strategies in diastolic heart failure. Heart 2010; 96: 14: 1147—1153.
10. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabet Metab 2004; 30: 487—496.
Review
For citations:
Tatarchenko I.P., Pozdnyakova N.V., Mordovina A.G. The clinical and instrumental rationale for the choice of therapy of arterial hypertension in the patients presenting with diabetes mellitus. Problems of Endocrinology. 2012;58(6):8-12. https://doi.org/10.14341/probl20125868-12
Views:
328
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
